Expanding indications for recombinant human TSH in thyroid cancer

Thyroid

Volumn 18, Issue 7, 2008, Pages 687-694

  Haugen, Bryan R ^a   Cooper, David S ^b   Emerson, Charles H ^c   Luster, Markus ^d   Maciel, Rui M B ^e   Biscolla, Rosa P M ^e   Mazzaferri, Ernest L ^f,g   Medeiros Neto, Geraldo ^h   Reiners, Christoph ⁱ   Robbins, Richard J ^j   Robinson, Bruce G ^k   Schlumberger, Martin ^l   Yamashita, Shunichi ^m   Pacini, Furio ⁿ  

^a UNIVERSITY OF COLORADO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ Klinik und Poliklinik für Dermatologie Venerologie und Allergologie   (Germany)

^j HOUSTON METHODIST HOSPITAL   (United States)

^k ROYAL NORTH SHORE HOSPITAL   (Australia)

^l INSTITUT GUSTAVE ROUSSY   (France)

^m NAGASAKI UNIVERSITY   (Japan)

ⁿ UNIVERSITY OF SIENA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ASIA; AUSTRALIA; CANCER SCINTISCANNING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HORMONAL THERAPY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IATROGENIC DISEASE; JAPAN; KIDNEY CLEARANCE; LACRIMAL DUCT; METASTASIS; MOUTH CAVITY; NORTH AMERICA; PAROTID GLAND; PATIENT CARE; PATIENT RIGHT; PATIENT SELECTION; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION ABSORPTION; RADIATION DOSE; REIMBURSEMENT; SOUTH AMERICA; THYROID CANCER; THYROID SCINTISCANNING; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

HUMANS; IODINE RADIOISOTOPES; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 47549098976     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0162     Document Type: Editorial

References (35)

1. Duntas LH, Cooper DS 2008 Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 18:509-516.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
4. Zanotti-Fregonara P, Toubert ME, Taieb D, Ravasi L, Rubello D, Hindie E 2008 Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular origin. Minerva Endocrinol 33:53-65.
5. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or thyroid hormone withdrawal. J Nucl Med 47:648-654.
6. Schlumberger M, Ricard M, de Pouvourville G, Pacini F 2007 How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab 3:641-650.
7. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885.
8. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
9. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW 2006 A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878-884.
10. Luster M, Felbinger R, Dietlein M, Reiners C 2005 Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15:1147-1155.
11. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, de Pouvourville G 2007 Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 156:531-538.
12. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR 2006 Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 155:405-414.
13. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546.
14. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 93:76-81.
15. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielni S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax E, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussiere F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E 2007 Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 92:2487-2495.
16. Potzi C, Moamenni A, Karanikas G, Preitfellner J, Becherer A, Pirch C, Dudczak R 2006 Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf ) 65:519-523.
17. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A 2002 Ablation of thyroid residues with 30mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068.
18. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896.
19. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A 1985 Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf ) 23:405-411.
20. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.
21. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasound has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
22. Pacini F, Lippi F 1999 Clinical experience with recombinant humanthyroid-stimulating hormone (rhTSH): Serum thyroglobulin measurement. J Endocrinol Invest 22(11 Suppl):25-29.
23. Mazzaferri EL, Robbins RJ, Braverman LE, Pacini F, Haugen B, Wartofsky L, Braunstein GD, Ladenson PW, Pinchera A 1988 Author reply: a consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:4508-4510.
24. Rubino C, Adjadi E, Guerin S, Guibout C, Shamsaldin A, Dondon MG, Valteau-Couanet D, Hartmann O, Hawkins M, de Vathaire F 2003 Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 10:791-796.
25. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47:1587-1591.
26. Kulkarni K, Nostrand DV, Atkins F, Aiken M, Berman K, Wartofsky L 2006 The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancers. Thyroid 16:1019-1023.
27. Perros P 1999 Recombinant human thyroid stimulating hormone (rhTSH) in the radioablation of well differentiated thyroid cancer: Preliminary therapeutic experience. J Endocrinol Invest 22:30-34.
28. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869.
29. Robbins RJ, Driedger A, Magner J; U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group 2006 Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16:1121-1130.
30. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645.
31. Maia AL, Ward LS, Carvalho GA, Graf H, Maciel RM, Maciel LM, Rosario PW, Vaisman M 2007 Thyroid nodules and differentiated thyroid cancer: Brazilian consensus. Arq Bras Endocrinol Metabol 51:867-893.
32. Barbaro D, Boni G 2007 Radioiodine ablation of postsurgical thyroid remnants after preparation with recombinant human TSH: why, how and when. Eur J Surg Oncol 33:535-540.
33. Rosario PW, Borges MA, Valadao MM, Vasconcelos FP, Rezende LL, Padrao EL, Barroso AL, Purisch S 2007 Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid 17:1225-1228.
34. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, de Pouvourville G 2007 Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 156:531-538.
35. Haugen BR 2000 Initial treatment of differentiated thyroid cancer. Rev Endocr Metab Disord 1:139-145.